Figure S1
S2 RP-HPLC purification of crude 22/9/9 GC probe after cleavage
Figure S2
S3 AX-HPLC purification of 22/9/9 GC probe after conjugation to (D-Arg) 9 cell-penetrating peptide
Figure S3
S4 RP-HPLC purification of crude PS-22/9/9 probe after solid-phase synthesis and cleavage
Figure S4
S5 FRET efficiencies of 18/7/7 and 22/9/9 TIVA probes in buffer, pre-photolysis
Figure S5
S6 RP-HPLC purification of crude 22/9/9 GC probe after solid-phase synthesis and cleavage
Figure S6
S7 AX-HPLC purification of 22/9/9 probe after conjugation to (D-Arg) 9 cell-penetrating peptide Figure S5 S8 RP-HPLC purification of cleaved 18/7/7 TIVA syntheses before and after protocol improvements Figure S1 . RP-HPLC purification of crude 22/9/9 GC probe after solid-phase synthesis and cleavage Separation was performed on C-18 column under a gradient of increasing acetonitrile in 0.5 M TEAA, with the product eluting at roughly 28 min. FRET efficiencies were measured for both probes at 1.0 µM in 1x STE buffer. 18/7/7 and 22/9/9 TIVA probes were synthesized according to [19] . Figure S5 . RP-HPLC purification of crude 22/9/9 GC probe after solid-phase synthesis and cleavage Separation was performed on C-18 column under a gradient of increasing acetonitrile in 0.5 M TEAA, with the product eluting at roughly 50 min. Figure S7 . RP-HPLC purification of cleaved 18/7/7 TIVA syntheses before and after protocol improvements RP-HPLC purification of six different 18/7/7 TIVA probe syntheses, three before (A) and three after (B) protocol improvements, resulting in more consistent syntheses with higher yield. Separation was performed on a C-18 column under a gradient of increasing acetonitrile in 0.5 M. TEAA, with the product eluting at roughly 51 min. Figure S8 . ESI-MS analysis of 22/9/9 +(D-Arg) 9 TIVA ESI-MS verified the product mass (16, 913 Da predicted, 16, 912 Da observed) . The principal impurity corresponeded to TIVA product with one missing 2´F-U (-307 Da), which is not expected to significantly impact probe performance. 
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